NCT00565721View on ClinicalTrials.gov

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

September 30, 2012

Conditions
High-grade GliomaLung CancerHead & Neck CancerSarcomaMelanoma
Interventions
DRUG

Fluciclatide Injection - (AH111585 (F18))

18F labelled Cyclic RGD peptide PET agent for injection.

Trial Locations (1)

08540

GE Healthcare Office, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY